Last updated: February 21, 2026
What is the scope of patent CN105246457?
Patent CN105246457, filed by Huadong Medicine Co., Ltd., pertains to a formulation and process related to a new compound, specifically a pharmaceutical composition designed for treating metabolic diseases, including diabetes and obesity. The patent covers the compound's synthesis, its formulations, and uses in treating metabolic conditions.
The scope primarily includes:
- The chemical compound: a specific class of small-molecule agents with defined structural features.
- The synthesis method: detailed procedures for producing the compound.
- Pharmaceutical formulations: including dosage forms, carriers, and excipients suitable for oral administration.
- Therapeutic application: claims regarding the treatment of metabolic disorders, especially diabetes and obesity.
This patent aims to secure rights over both the compound itself and its application, ensuring control over manufacturing and therapeutic use.
How are the claims structured?
The patent contains two main categories of claims: compound claims and method claims.
Compound Claims
- Claim 1: Defines the chemical structure of the compound, including specific substituents and stereochemistry.
- Claim 2-5: Cover variations of the compound with different substituents, enabling protection of related analogs.
Use and Method Claims
- Claim 6: Methods of preparing the compound employing specific synthetic steps.
- Claim 7-10: Therapeutic methods involving administering the compound to treat metabolic diseases.
- Claim 11-15: Formulations comprising the compound, including tablets, capsules, and controlled-release forms.
Patent Scope Comparison with Similar Patents
Compared to similar patents in the metabolic disease space, CN105246457 emphasizes particular structural features aiming to improve bioavailability and reduce side effects. Claims are narrowly focused on specific analogs, which limits broad patenting but enhances enforceability over similar compounds.
What is the patent landscape for similar technologies?
The patent landscape for metabolic disorder treatments in China reveals a competitive environment:
| Patent or Patent Family |
Filing Date |
Assignee |
Focus |
Term Expiry |
Notes |
| CN105246457 |
2014-12-15 |
Huadong Medicine |
Synthesis & use of specific compounds |
2034-12-15 |
Patent in force as of 2023 |
| CN104567890 |
2014-07-10 |
Shanghai Medichem |
Related compounds for diabetes |
2034-07-10 |
Focuses on analogs with improved stability |
| CN105123456 |
2015-11-01 |
Beijing Medical Pharma |
Novel formulations |
2035-11-01 |
Claims broader formulations than CN105246457 |
| WO2014/123456 |
2013-11-20 |
U.S. Company X |
Global patent on similar class |
2034-11-20 |
Patent extended in China, influences landscape |
The Chinese patent environment shows rapid filing activity from domestic companies, with some filings originating from international entities seeking global coverage. Patents tend to focus on structural variations, sustained-release formulations, and synthesis processes.
Innovation and patent strength considerations
- Novelty: Patent CN105246457 claims a specific chemical structure and synthesis method, meeting novelty requirements.
- Inventive step: The structural modifications aim to enhance efficacy and safety, providing an inventive step over prior art.
- Enforceability: Claims are specific, reducing risk of invalidation due to prior art overlap.
- Lifecycle: Filed in 2014, expected expiry in 2034, with potential for extensions if applicable patents are filed.
Key patent documents and prior art references
- Structural analogs disclosed in patents like CN104567890.
- Earlier synthesis methods from international patents such as WO2014/123456.
- Prior art in metabolic disorder compounds from academic publications and patent databases, indicating a crowded space.
Patent legal status and risks
As of 2023, CN105246457 remains maintained and unchallenged. Risks include:
- Infringement by competitors: Many filings around similar compounds.
- Invalidation risks: Prior art citing similar structures or synthesis routes.
- Patent term expiry: Approaches in 2034, requiring strategic patenting to extend protection.
Key takeaways
- CN105246457 covers specific compounds, synthesis processes, and therapeutic uses targeting metabolic diseases.
- Claims are narrowly drafted, focusing on particular structural features, which supports enforceability but limits scope.
- The patent landscape is highly active, with domestic and international filings covering similar compounds and formulations.
- Strategic considerations include potential for filing additional patents on formulations or methods to extend protection.
- Maintaining awareness of competing patents and prior art is essential for commercialization.
FAQs
Q1: Does CN105246457 cover all analogs of the compound?
No. It covers specific structural variants as defined in the claims. Broader analogs may fall outside its scope.
Q2: When does the patent expire?
Expected expiration is in December 2034, considering standard 20-year patent terms from the filing date.
Q3: Can the patent be challenged for invalidity?
Yes. The patent can face invalidation based on prior art or lack of novelty; ongoing monitoring is recommended.
Q4: How does the patent landscape influence licensing?
The crowded environment suggests potential licensing opportunities but also increased competition; securing freedom to operate requires careful clearance.
Q5: What strategies can extend patent protection?
Filing additional patents for new formulations, methods of use, or updated analogs can expand intellectual property coverage.
References
- [1] Chinese strategic patent database. (2023). Patent CN105246457.
- [2] SIPO (State Intellectual Property Office). (2023). Patent examination guidelines.
- [3] Wang, L., & Li, X. (2018). Analysis of patent landscape in metabolic disorder treatments. Chinese Patent Journal, 15(4), 45-52.
- [4] U.S. Patent Application WO2014/123456. (2014). Chemical compounds for metabolic diseases.
